Food Safety Incidents

Irregular Advertising has been detected in Food Supplement Variety.

Written by SGS Digicomply Editorial Team | Mar 31, 2026 10:00:00 PM

Incident Report: Irregular Advertising in Food Supplement Variety

Date of Incident: March 19, 2026

The Brazilian Health Regulatory Agency (ANVISA) has identified an issue concerning irregular advertising practices associated with a food supplement variety. This incident falls under the category of control and is classified as an inadvertent deviation. Such deviations can pose potential risks to consumers, as misleading information may affect their choices regarding dietary supplements.

Food supplements are intended to enhance the diet and provide essential nutrients that may be lacking in regular food intake. However, accurate and transparent advertising is crucial to ensure consumer safety and informed decision-making. Irregularities in advertising can lead to confusion about the product's benefits, ingredients, and usage, which may ultimately compromise food safety standards.

It is essential for consumers to remain vigilant and critically assess the information presented in advertisements for food supplements. Regulatory bodies like ANVISA play a vital role in monitoring and enforcing compliance with advertising standards to protect public health.

As this situation develops, stakeholders in the food industry, including manufacturers and retailers, are urged to adhere strictly to advertising regulations to maintain consumer trust and ensure the safety of food supplements in the market.

  • Incident: Irregular Advertising has been detected in Food Supplement Variety.
  • Date: 2026-03-19
  • Product: Food Supplement Variety
  • Market: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Origin of issue: Brazil
  • Hazard: Available to SGS Digicomply users only. Explore the platform (for enterprises, no individual plans)
  • Incident Category: Control
  • Hazard Category: Inadvertent Deviations
  • Source: Brazilian Health Regulatory Agency - ANVISA